- Home
- Healthcare
-
Single-use Bioreactors Market
Single-use Bioreactors Market Analysis, Size, Share, By Product Type (Stirred-Tank Bioreactors, Wave-Induced/Rocking Bioreactors, Bubble Column Bioreactors), By Cell Type (Mammalian Cells, Bacterial Cells, Yeast Cells), By Application (Monoclonal Antibody Production, Vaccine Production, Stem Cell Culture), By End-User (Biopharmaceutical & Pharmaceutical Companies, Contract Manufacturing Organizations, Contract Research Organizations), By Molecule Type (Monoclonal Antibodies, Vaccines, Recombinant Proteins), and Region - Forecast 2025-2033
Industry : Healthcare | Pages : 225 Pages | Published On : Nov 2025
The global Single-use Bioreactors Market is experiencing robust growth, driven by several key factors. Economic expansion, particularly in emerging markets like China, has led to increased investments in healthcare infrastructure, fostering a conducive environment for biopharmaceutical advancements. Technological innovations, such as the development of large-scale SUBs and advancements in automation, have enhanced production efficiency and scalability. These innovations are crucial in meeting the rising demand for biologics, including monoclonal antibodies, vaccines, and gene therapies.
Additionally, the growing prevalence of lifestyle-related diseases and aging populations worldwide have escalated the need for personalized medicine, further propelling the demand for flexible and cost-effective biomanufacturing solutions. The adoption of SUBs offers significant advantages, including reduced capital investment, minimized risk of cross-contamination, and shorter production timelines, making them increasingly preferred over traditional stainless-steel systems in biopharmaceutical manufacturing.
Key players in the single-use bioreactors market are actively expanding their capabilities through strategic initiatives. Companies like Thermo Fisher Scientific and Merck KGaA have introduced large-scale SUB systems, such as the 3,000 L and 5,000 L HyPerforma DynaDrive bioreactors, to cater to the growing demand for large-volume production. Additionally, collaborations and partnerships are being formed to enhance technological capabilities and market reach.
For instance, Getinge AB's launch of the Single-Use Production Reactor (SUPR) system in 2024 exemplifies the industry's focus on innovation to meet evolving market needs. These developments underscore the dynamic and competitive landscape of the single-use bioreactors market, with companies striving to leverage technological advancements and strategic partnerships to maintain a competitive edge in the rapidly evolving biopharmaceutical sector.
Single-use Bioreactors Market Latest and Evolving Trends
Current Market Trends
The single-use bioreactors market is witnessing robust growth driven by technological advancements that enhance process efficiency, scalability, and reproducibility. The integration of miniaturized systems allows for reduced footprint, lower contamination risk, and streamlined workflows, making them ideal for modern biopharmaceutical manufacturing. The use of advanced biocompatible materials ensures optimal cell growth and protein production while minimizing the risk of adverse reactions. Increasing prevalence of cardiovascular diseases, coupled with aging populations, has intensified the demand for biologics and personalized therapies, thereby expanding bioreactor adoption.
Upgraded healthcare infrastructure and hospital modernization programs further facilitate the integration of single-use technologies into clinical and production settings. Furthermore, expanding research and development initiatives are enabling faster product development and flexible manufacturing. Strategic alliances and collaborations between bioreactor manufacturers and regional stakeholders are accelerating market penetration. Adoption is particularly strong in hospitals and specialized cardiac centers where reliable and scalable production solutions are critical.
Market Opportunities
Opportunities in the single-use bioreactors market are expanding rapidly, particularly in emerging regions such as Asia-Pacific, where healthcare infrastructure is modernizing and demand for advanced biologics is rising. The ongoing shift toward personalized medicine and regenerative therapies opens avenues for innovative product development, including modular and fully automated bioreactor systems. Miniaturized and disposable platforms reduce operational costs and allow small-scale, rapid-scale-up production suitable for early-stage research and clinical trials.
Strategic partnerships and regional collaborations offer potential for local manufacturing and distribution, optimizing supply chains and reducing time-to-market. Hospitals and specialized cardiac centers increasingly prefer single-use systems due to their ease of use, flexibility, and ability to minimize cross-contamination risks. Advancements in biocompatible materials enhance process reliability and extend product shelf-life, creating additional commercial opportunities. Moreover, integration of digital monitoring and process control solutions enables real-time optimization, increasing efficiency and reproducibility. Expanding R&D activities in novel biologics and vaccines further underpin market potential, driving continuous adoption across the healthcare sector.
Evolving Trends
The single-use bioreactors landscape is evolving with the advent of innovation-led product portfolios emphasizing automation, scalability, and operational efficiency. Technological advancements are enabling smart sensors, predictive analytics, and automated process controls, facilitating higher yields and reduced downtime. Miniaturization is a key trend, allowing parallel processing, enhanced process development, and laboratory-to-commercial scale transition without significant infrastructure changes. Biocompatible materials continue to improve, reducing leachables and extractables while maintaining cellular viability and product quality.
Rising cardiovascular cases, aging populations, and upgraded healthcare facilities are driving sustained adoption, particularly in hospital and specialized cardiac centers. Strategic alliances and regional collaborations are fostering knowledge sharing, enabling localized solutions tailored to specific market requirements. Increasing focus on Asia-Pacific markets presents new growth avenues, supported by expanding healthcare budgets and research initiatives. Overall, the market is shifting towards fully integrated, flexible, and innovation-driven solutions that cater to both small-scale research and large-scale commercial production, ensuring long-term growth and resilience.
Single-use Bioreactors Market: Emerging Investment Highlights
The single-use bioreactors market is experiencing robust growth, projected to expand from USD 4.4 billion in 2024 to USD 9.1 billion by 2029, reflecting a compound annual growth rate (CAGR) of 15.4%. This surge is driven by the increasing adoption of single-use technologies by Contract Development and Manufacturing Organizations (CDMOs), Contract Manufacturing Organizations (CMOs), and small to medium-sized enterprises (SMEs). These bioreactors offer significant advantages over traditional stainless-steel systems, including reduced capital investment, lower contamination risks, and enhanced scalability. Notably, stirred-tank single-use bioreactors dominate the market, accounting for 80% of the share and growing at a CAGR of 14%. This trend underscores the industry's shift towards more flexible and cost-effective manufacturing solutions.
Recent Company Developments
- Getinge AB: In March 2024, Getinge launched the Single-Use Production Reactor (SUPR) system, available in 50-liter and 250-liter sizes, catering to the growing demand for scalable bioprocessing solutions.
- Merck KGaA: In April 2023, Merck introduced the Ultimus single-use process container film, designed to provide extreme durability and leak resistance for single-use assemblies used in bioprocessing liquid applications.
Single-use Bioreactors Market Limitations
Despite their advantages, single-use bioreactors face several challenges that could impact market growth. High production costs remain a significant concern, as the specialized materials and complex supply chain requirements contribute to elevated expenses. Additionally, regulatory hurdles and compliance issues can delay the approval and adoption of these systems. Another limitation is the risk of breakage of single-use bags and concerns related to leachables and extractables, which may impede the growth of the market. Ensuring sterility during assembly and operation also adds complexity, potentially affecting the reliability and consistency of performance from bag to bag.
Single-use Bioreactors Market Drivers
1. Rising Demand for Biopharmaceuticals
The increasing prevalence of chronic diseases and the growing demand for biologics are propelling the need for efficient and scalable manufacturing solutions. Single-use bioreactors facilitate the rapid production of therapeutic proteins, monoclonal antibodies, and vaccines, aligning with the industry's shift towards personalized medicine and gene therapies. This trend is particularly evident in North America, where the biopharmaceutical sector is expanding rapidly, driven by supportive government initiatives and substantial investments in research and development.
2. Technological Advancements in Bioprocessing
Advancements in automation, artificial intelligence, and machine learning are enhancing the efficiency and flexibility of bioprocessing. Single-use bioreactors, with their modular design and reduced cleaning requirements, integrate seamlessly into modern manufacturing environments. These technological innovations enable faster turnaround times, reduced contamination risks, and lower operational costs, making single-use systems increasingly attractive to biopharmaceutical manufacturers seeking to streamline production processes.
3. Strategic Industry Collaborations
Collaborations between technology providers and biopharmaceutical companies are accelerating the development and adoption of single-use bioreactors. These partnerships focus on addressing specific industry needs, such as improving system durability, enhancing scalability, and ensuring regulatory compliance. By combining expertise in bioprocessing and equipment manufacturing, these alliances are driving the evolution of single-use technologies, positioning them as a cornerstone of future biopharmaceutical production.
Segmentation Highlights
Product Type, Cell Type, Application, End-User, Molecule Type and Geography are the factors used to segment the Global Single-use Bioreactors Market.
By Product Type
- Stirred-Tank Bioreactors
- Wave-Induced/Rocking Bioreactors
- Bubble Column Bioreactors
- Hybrid Bioreactors
- Other Systems
By Cell Type
- Mammalian Cells
- Bacterial Cells
- Yeast Cells
- Other Cell Types
By Application
- Monoclonal Antibody Production
- Vaccine Production
- Stem Cell Culture
- Plant Cell Culture
- Other Biologics
By End-User
- Biopharmaceutical & Pharmaceutical Companies
- Contract Manufacturing Organizations
- Contract Research Organizations
- Academic & Research Institutes
By Molecule Type
- Monoclonal Antibodies
- Vaccines
- Recombinant Proteins
- Stem Cells
- Gene Therapy Products
Regional Overview
North America dominates the Edge AI Software Market with a market size of $2.0 billion in 2025, maintaining a steady CAGR of 18.9% due to early adoption of advanced technologies, supportive infrastructure, and strong presence of AI-focused enterprises. Asia-Pacific is identified as the fastest-growing region, projected to grow at a CAGR of 21.5% and reach $1.3 billion by 2030, supported by increasing digital transformation initiatives, expanding industrial automation, and government incentives for AI integration. Europe holds a market value of $1.1 billion with a CAGR of 17.8%, driven by manufacturing, automotive, and healthcare AI deployments. Other regions, including Latin America and the Middle East & Africa, collectively account for $750 million, with a CAGR of 16.5%, reflecting gradual adoption of edge AI technologies across emerging sectors and the rising need for localized analytics solutions.
Global Competition and Regional Competition in the Single‑Use Bioreactors Industry
The global single‑use bioreactors (SUB) industry is rapidly evolving into a high‑stakes arena where technology leadership, regional manufacturing footprint and strategic partnerships determine competitive advantage. Globally, the market was estimated to be valued at about **USD 4.17 billion in 2024**, with projections indicating growth to around **USD 23.7 billion by 2035**, implying a compound annual growth rate (CAGR) in the mid‑teens. Key drivers include the surge in biologics manufacturing, cell and gene therapy pipelines, increased outsourcing to CDMOs and the need for modular, agile facilities. The competitive ecosystem features a handful of global leaders commanding significant market shares; for example one firm alone is cited as having near 28 % share globally, while another holds approximately 22 %.
Regionally, the dynamics differ substantially:
- North America (particularly the U.S.): This region remains the largest single market and manufacturing base for single‑use bioreactors, supported by a dense presence of large biopharmaceutical companies, CDMOs, regulatory support and mature supply chains. Estimates suggest North America accounts for approximately 38 % of the market share. Regional competition revolves around innovation in large‑scale SUB systems (e.g., beyond 1,000 L) and integration of sensor, automation and hybrid production capabilities.
- China and Asia‑Pacific: Asia-Pacific is emerging as the fastest growth region. Key factors include rising biomanufacturing investments in China, India and Southeast Asia, a growing CRO/CMO ecosystem and increasing domestic demand for biologics. For the Asia‑Pacific region, growth rates exceed those in mature markets, and the region is cited as capturing around 25 % of the market. Local players and global entrants are competing to build capacity and localised supply chain, especially in China, with China‑based firms seeking to move up the value chain from components to full SUB systems.
- India: While India currently represents a smaller portion of the global single‑use bioreactor market, in the context of biopharma manufacturing growth it offers a significant opportunity. Local manufacturing, partnerships with global SUB vendors, and CDMO expansions are enabling India to become part of the competitive ecosystem. Domestic competition in India focuses more on system integration services, component supply, and regional servicing rather than full‑scale platform development — but over time the gap is narrowing.
- Europe: With a strong base in innovation and regulation, Europe remains a key competitive region. Players often site manufacturing, R&D and standardisation efforts here. Growth is steady but more measured compared with Asia‑Pacific.
Across all regions the competitive edge is increasingly defined by the ability to deliver scalable single‑use platforms (from lab/bench‑scale to commercial manufacture), advanced process monitoring and automation, sustainability (reduced footprint, lower utility use), and ease of integration into hybrid or continuous production lines. One recent data set notes that approximately 58 % of new manufacturing facilities globally are prioritising single‑use technologies, while 46 % of biotech start‑ups are allocating funding towards disposable systems to accelerate development.
Major Key Companies in the Single‑Use Bioreactors Industry
- Company A: A global leader with close to 28 % market share; strong in stirred‑tank single‑use systems and rapid scale‑up capability.
- Company B: A large U.S.‑based life‑sciences firm capturing about 22 % of the global market; known for broad product portfolio and global distribution.
- Company C: A German‑based specialist, frequently cited among the top tier, with strong innovation in bioprocessing platforms and single‑use bioreactor systems.
- Company D: A diversified technologies firm (including bioprocessing consumables) engaged in single‑use bioreactor solutions and related ancillary products.
- Company E: An established player focusing on laboratory‑scale and development‑scale single‑use bioreactors; part of the broader competitive set.
While many other companies compete, these five represent the core of the market both in terms of volume, technology leadership and global reach.
Recent Single‑Use Bioreactors Industry Development
The SUB industry has witnessed several meaningful recent developments (2024 onwards) in research & development, mergers & acquisitions, capacity expansion and technological innovation:
- In March 2024, one major player announced launch of a next‑generation single‑use bioreactor system with enhanced mixing and aeration designed to improve scalability and reduce process variability in commercial biologics manufacture.
- In April 2024, another firm introduced a magnetic mixer for 2,000 L and 3,000 L single‑use systems specifically tailored for monoclonal antibody and gene therapy manufacturing, enabling improved performance at large scale.
- In Q1 2024 one of the European firms invested approximately €130 million in a new single‑use assembly production facility in France, demonstrating commitment to scale manufacturing of single‑use assemblies to support biopharma demand.
- In Asia‑Pacific, a Chinese firm completed its first commercial campaign using three 5,000 L single‑use bioreactors in a new drug substance line, signifying the region’s growing capability in large‑volume SUB manufacturing.
- On the M&A front, a leading life‑sciences company announced acquisition of a purification and filtration unit (~US$4.1 billion) in early 2025, positioning it to integrate upstream single‑use reactor systems with downstream purification workflows, thereby offering more complete bioprocessing solutions.
- From a market‑size and segmentation perspective, the lab‑scale segment (e.g., up to 10 L systems) still captured the largest revenue share in 2024 (around 35.6 %), but the large‑scale production segment (commercial manufacturing) is anticipated to grow at the fastest CAGR (~18.2 %) over the next decade.
- Analytical data point: one report suggests that roughly 63 % increase in biologics demand, 52 % rise in automation usage, and a 47 % improvement in manufacturing scalability are among the key underlying drivers shaping the SUB ecosystem.
Taken together, these developments reveal a maturing market wherein players are shifting from niche, benchtop systems toward large‑volume, fully integrated manufacturing lines, while regionally Asia‑Pacific (especially China) is closing the gap with the matured U.S. and European markets. At the same time, strategic mergers, capacity expansion, and technological leaps in sensor integration, magnetic mixing, and automation are elevating the competitive bar.
Cloud Engineering Market Size, Share & Trends Analysis, By Deployment (Public, Private, Hybrid), By Service (IaaS, PaaS, SaaS), By Workload, By Enterprise Size By End-use, By Region, And Segment Forecasts
TOC
Table and Figures
Methodology:
At MarketDigits, we take immense pride in our 360° Research Methodology, which serves as the cornerstone of our research process. It represents a rigorous and comprehensive approach that goes beyond traditional methods to provide a holistic understanding of industry dynamics.
This methodology is built upon the integration of all seven research methodologies developed by MarketDigits, a renowned global research and consulting firm. By leveraging the collective strength of these methodologies, we are able to deliver a 360° view of the challenges, trends, and issues impacting your industry.
The first step of our 360° Research Methodology™ involves conducting extensive primary research, which involves gathering first-hand information through interviews, surveys, and interactions with industry experts, key stakeholders, and market participants. This approach enables us to gather valuable insights and perspectives directly from the source.
Secondary research is another crucial component of our methodology. It involves a deep dive into various data sources, including industry reports, market databases, scholarly articles, and regulatory documents. This helps us gather a wide range of information, validate findings, and provide a comprehensive understanding of the industry landscape.
Furthermore, our methodology incorporates technology-based research techniques, such as data mining, text analytics, and predictive modelling, to uncover hidden patterns, correlations, and trends within the data. This data-driven approach enhances the accuracy and reliability of our analysis, enabling us to make informed and actionable recommendations.
In addition, our analysts bring their industry expertise and domain knowledge to bear on the research process. Their deep understanding of market dynamics, emerging trends, and future prospects allows for insightful interpretation of the data and identification of strategic opportunities.
To ensure the highest level of quality and reliability, our research process undergoes rigorous validation and verification. This includes cross-referencing and triangulation of data from multiple sources, as well as peer reviews and expert consultations.
The result of our 360° Research Methodology is a comprehensive and robust research report that empowers you to make well-informed business decisions. It provides a panoramic view of the industry landscape, helping you navigate challenges, seize opportunities, and stay ahead of the competition.
In summary, our 360° Research Methodology is designed to provide you with a deep understanding of your industry by integrating various research techniques, industry expertise, and data-driven analysis. It ensures that every business decision you make is based on a well-triangulated and comprehensive research experience.
• Product Planning Strategy
• New Product Stratergy
• Expanded Research Scope
• Comprehensive Research
• Strategic Consulting
• Provocative and pragmatic
• Accelerate Revenue & Growth
• Evaluate the competitive landscape
• Optimize your partner network
• Analyzing industries
• Mapping trends
• Strategizing growth
• Implementing plans
Covered Key Topics
Growth Opportunities
Market Growth Drivers
Leading Market Players
Company Market Share
Market Size and Growth Rate
Market Trend and Technological
Research Assistance
We will be happy to help you find what you need. Please call us or write to us:
+1 510-730-3200 (USA Number)
Email: sales@marketdigits.com
